Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial. (linkinghub.elsevier.com)

Authors: Noureddin M … Loomba R Journal: The Lancet Published: 2026-02-21 DOI: https://doi.org/10.1016/S0140-6736(25)02276-7